SCHEMBL4024019

SCHEMBL4024019

Fc1ccccc1-c1cn2nc(Cl)ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 2/20 0.46
DRD2 P14416 3/20 0.39
DRD4 P21917 3/20 0.39
DRD3 P35462 3/20 0.39
NPC1 O15118 2/20 0.37
MPL P40238 1/20 0.37
KDM4E B2RXH2 2/20 0.37
TLR8 Q9NR97 1/20 0.36
AHR P35869 1/20 0.36
HTR1A P08908 2/20 0.36
ADRA1D P25100 2/20 0.36
ADRA1A P35348 2/20 0.36
ADRA1B P35368 2/20 0.36
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
RAB9A P51151 2/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13750599 0.82 F2RL3 (0.49) F2RL3NPC1MPLTLR8AHR
SCHEMBL10277867 0.82 CSNK1D (0.40) F2RL3NPC1MPLAHRTP53
SCHEMBL13730155 0.78 F2RL3 (0.46) F2RL3NPC1MPLTLR8AHR
SCHEMBL13745560 0.78 F2RL3 (0.46) F2RL3NPC1MPLTLR8AHR
SCHEMBL3108835 0.78 NPC1 (0.54) NPC1KDM4ERAB9ATP53GAA
SCHEMBL1395044 0.75 DRD2 (0.49) F2RL3DRD2DRD4DRD3NPC1
SCHEMBL4021715 0.74 CCR1 (0.45) DRD2DRD4DRD3NPC1KDM4E
SCHEMBL4099914 0.74 DRD2 (0.42) F2RL3DRD2DRD4DRD3NPC1
SCHEMBL4024150 0.74 F2RL3 (0.48) F2RL3DRD2DRD4DRD3NPC1
SCHEMBL22614984 0.71 NPC1 (0.57) F2RL3DRD2DRD4DRD3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
WO-2009095377-A1 SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2009-08-06 WO disclosed
WO-2009095377-A1 SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists NPY4R, NPY1R, NPY5R F2RL3 449/4885DRD2 160/4885DRD4 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.